J

Researcher Profile

J.-Y. Han

3

Publications

345

Citations

10

Co-Authors

3

Active Years

Publications

Open Access Journal Article Annals of Oncology Feb 01, 2022

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

R.A. Soo · J.-Y. Han · U. Dafni · B.C. Cho +87 more

10.1016/j.annonc.2021.11.010 85 citations

Open Access Journal Article Annals of Oncology Nov 01, 2020

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

V.A. Papadimitrakopoulou · T.S. Mok · J.-Y. Han · M.-J. Ahn +16 more

10.1016/j.annonc.2020.08.2100 227 citations

Open Access Journal Article Annals of Oncology Oct 01, 2018

Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)

J. Wolf · T. Seto · J.-Y. Han · N. Reguart +14 more

10.1093/annonc/mdy424.090 33 citations

Publication Timeline

2022

1

2020

1

2018

1

Frequent Co-Authors

Meghan McGrillen

Magdalena Sanchez-Hohl

M. Provencio Pulla